TAC-PF, Avastin® in Combination With Photodynamic Therapy to Treat Age Related Macular Degeneration

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2007
VERTACL will investigate whether a triple therapy, Avastin®, half fluence verteporfin photodynamic therapy (PDT), and triamcinolone acetonide-preservative free (TAC- PF), results in improved 12-month vision outcome compared to Avastin® alone in participants with neovascular AMD.
Epistemonikos ID: 53168ded567ff52de59c2eb6f0c4495f55243ae8
First added on: May 04, 2024